John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the patient profile that is best suited for zanubrutinib in relapsed or refractory mantle cell lymphoma (MCL)
Zanubrutinib in Relapsed or Refractory MCL
